ASLAN Pharmaceuticals Ltd ADR ASLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASLN is a good fit for your portfolio.
News
-
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
-
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
-
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
-
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
-
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
-
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
-
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
Trading Information
- Previous Close Price
- $0.46
- Day Range
- $0.44–0.47
- 52-Week Range
- $0.39–4.69
- Bid/Ask
- $0.45 / $0.46
- Market Cap
- $10.12 Mil
- Volume/Avg
- 292,541 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.aslanpharma.com
Valuation
|
Metric
|
ASLN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.61 |
Price/Cash Flow | — |
Price/Earnings
ASLN
Financial Strength
|
Metric
|
ASLN
|
|---|---|
Quick Ratio | 1.63 |
Current Ratio | 1.84 |
Interest Coverage | −9.28 |
Quick Ratio
ASLN
Profitability
|
Metric
|
ASLN
|
|---|---|
Return on Assets (Normalized) | −91.82% |
Return on Equity (Normalized) | −2,159.76% |
Return on Invested Capital (Normalized) | −109.07% |
Return on Assets
ASLN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wvsgbrcm | Wntys | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hfglxbkq | Yswwc | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qlbktyr | Tskfspq | $103.7 Bil | |
MRNA
| Moderna Inc | Gdgdqgjl | Gln | $47.9 Bil | |
ARGX
| argenx SE ADR | Dhdtgvncl | Jqbw | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Vbhcnwmq | Xpxpn | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xptqmdbl | Lgtgl | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kcqfjwyk | Dczssg | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mbqypcmt | Njgycq | $12.8 Bil | |
INCY
| Incyte Corp | Hcccfkv | Rtndhx | $12.1 Bil |